Daily Sedation Interruption in Mechanically Ventilated Critically Ill Patients Cared for With a Sedation Protocol
A Randomized Controlled Trial

Sangeeta Mehta, MD
Lisa Burry, PharmD
Deborah Cook, MD
Marilyn Steinberg, RN
John Granton, MD
Margaret Herridge, MD
Niall Ferguson, MD
John Devlin, PharmD
Maged Tanios, MD
Peter Dodek, MD
Robert Fowler, MD
Karen Burns, MD
Michael Jacka, MD
Kendiss Olafson, MD
Yoanna Skrobik, MD
Paul Hébert, MD
Elham Sabri, MSc
Maureen Meade, MD
for the SLEAP Investigators and the Canadian Critical Care Trials Group

Context Protocolized sedation and daily sedation interruption are 2 strategies to minimize sedation and reduce the duration of mechanical ventilation and intensive care unit (ICU) stay. We hypothesized that combining these strategies would augment the benefits.

Objective To compare protocolized sedation with protocolized sedation plus daily sedation interruption in critically ill patients.

Design, Setting, and Patients Randomized controlled trial of 430 critically ill, mechanically ventilated adults conducted in 16 tertiary care medical and surgical ICUs in Canada and the United States between January 2008 and July 2011.

Intervention Continuous opioid and/or benzodiazepine infusions and random allocation to protocolized sedation (n=209) (control) or to protocolized sedation plus daily sedation interruption (n=214). Using validated scales, nurses titrated infusions to achieve light sedation. For patients receiving daily interruption, nurses resumed infusions, if indicated, at half of previous doses. Patients were assessed for delirium and for readiness for unassisted breathing.

Main Outcome Measure Time to successful extubation. Secondary outcomes included duration of stay, doses of sedatives and opioids, unintentional device removal, delirium, and nurse and respiratory therapist clinical workload (on a 10-point visual analog scale [VAS]).

Results Median time to successful extubation was 7 days in both the interruption and control groups (median [IQR], 7 [4-13] vs 7 [3-12]; interruption group hazard ratio, 1.08; 95% CI, 0.86-1.35; P=.52). Duration of ICU stay (median [IQR], 10 [5-17] days vs 10 [6-20] days; P=.36) and hospital stay (median [IQR], 20 [10-36] days vs 20 [10-48] days; P=.42) did not differ between the daily interruption and control groups, respectively. Daily interruption was associated with higher mean daily doses of midazolam (102 mg/d vs 82 mg/d; P=.04) and fentanyl (median [IQR], 550 [50-1850] vs 260 [0-1400]; P<.001) and more daily boluses of benzodiazepines (mean, 0.253 vs 0.177; P=.007) and opiates (mean, 2.18 vs 1.79; P<.001). Unintentional endotracheal tube removal occurred in 10 of 214 (4.7%) vs 12 of 207 patients (5.8%) in the interruption and control groups, respectively (relative risk, 0.82; 95% CI, 0.36-1.84; P=.83). Nurse workload was greater in the interruption group (VAS score, 4.22 vs 3.80; mean difference, 0.41; 95% CI, 0.17-0.66; P=.001).

Conclusion For mechanically ventilated adults managed with protocolized sedation, the addition of daily sedation interruption did not reduce the duration of mechanical ventilation or ICU stay.

Trial Registration clinicaltrials.gov Identifier: NCT00675363

Published online October 17, 2012. doi:10.1001/jama.2012.13872
www.jama.com

For editorial comment see p 2030.

Author Audio Interview available at www.jama.com.
mize sedation. Daily interruption of sedative infusions may achieve the same goal if infusions are resumed only when necessary and at half the previous dose. Early clinical trials evaluating each strategy led to strong recommendations for their use in practice. However, results of subsequent clinical trials varied, and use of these strategies in clinical practice has been inconsistent. Concerns about daily interruption of sedation include patient discomfort, unintentional device removal, and increased clinician workload. A systematic review of 5 trials that evaluated daily interruption highlighted the need for further research.

Avoiding excessive sedation is intuitively appealing. In light of the observed and potential benefits of both protocolized sedation and daily interruption in some settings, we hypothesized that mechanically ventilated adults managed with both strategies would receive less sedation and have a shorter duration of mechanical ventilation than patients managed with protocolized sedation alone.

**Randomization and Masking**

Research staff randomized patients to protocolized sedation plus daily interruption (interruption group) or protocolized sedation alone (control group), using an automated telephone system that stratified by center with undisclosed variable block sizes. None of the participants, study personnel, clinicians, or investigators analyzing data was masked to group assignment.

**Procedures**

Bedside nurses titrated analgesic and sedative infusions according to a protocol that prioritized pain assessment (eFigures 1 and 2, available at http://www.jama.com). Morphine, fentanyl, or hydromorphone was administered for analgesia; midazolam or lorazepam, for sedation. Nurses used the Sedation-Agitation Scale (8 sites) (eTable 1) or the Richmond Agitation Sedation Scale (8 sites) (eTable 2) to assess sedation needs hourly and titrated infusions to maintain, ideally, a comfortable yet rousable state equivalent to a Sedation-Agitation Scale score of 3 or 4 or Richmond Agitation Sedation Scale score of −3 to 0. When the sedation score directed an increase in medication, the bedside nurse judged whether to increase the opioid and/or benzodiazepine infusions. When patients were oversedated, nurses alternately reduced opioid and benzodiazepine infusions. Midazolam and morphine were reduced in 1- to 2-mg decrements, fentanyl in 12.5- to 25-μg decrements, and hydromorphone in 0.1- to 0.5-mg decrements at 15- to 30-minute intervals. If doses of midazolam, lorazepam, or morphine were less than 3 mg/h, 0.5-mg decrements could be used. If Sedation-Agitation Scale score was 1 to 2 (Richmond Agitation Sedation Scale score −4 or −5), yet the patient showed signs of agitation or distress, bolus doses were administered as needed. When patients were extremely agitated (Sedation-Agitation Scale score 7, Richmond Agitation Sedation Scale score 3 or 4), nurses could deviate from this protocol. For both groups, infusions were discontinued when a patient was oversedated (Sedation-Agitation Scale score 1 or 2; Richmond Agitation Sedation Scale score −4 or −5) while receiving 0.5 to 1 mg/h of midazolam or morphine (or fentanyl, 12.5-25 μg/h). Intermittent dosing was permitted for procedures. Propofol, ketamine, and dexmedetomidine infusions were not permitted.

In the interruption group, bedside nurses interrupted benzodiazepine and opioid infusions daily and assessed hourly for wakefulness, defined as Sedation-Agitation Scale score 4 to 7 (Richmond Agitation Sedation Scale score −1 to 4) and ability to perform at least 3 of the following on request: eye opening, tracking, hand squeezing, and toe moving. If the bedside nurse and a physician agreed that infusions were no longer required (the patient was free of discomfort and agitation and the Sedation-Agitation Scale score was between 2 and 5 or the Richmond Agitation Sedation Scale score was between −4 and 1), oral or bolus intravenous therapy was used at their discretion. Alternatively, if they judged that ongoing benzodiazepine or opioid infusions were required, nurses resumed infusions at half of the previous dose and titrated to achieve the target level of light sedation. If a patient became agitated (Sedation-Agitation Scale score 6 or 7 or Richmond Agitation Sedation Scale score 2 to 4) or exhibited signs of discomfort (respiratory rate >35/min, oxygen saturation as measured by pulse oximetry <90%, heart rate >140/min or a change in heart rate of 20% in either direction, systolic blood pressure >180 mm Hg, or increased anxiety and diaphoresis) before the physician’s assessment, nurses promptly resumed infusions at half the previous rate. Daily interruption could be delayed for procedures. When an interruption was not performed or infusions were not restarted at 50% of the previous dosage, the primary reason was documented. We also recorded any interruption of benzodiazepine and opioid infusions among control patients.

**Participants**

Eligible critically ill adults were those expected by the intensive care unit (ICU) team to require mechanical ventilation for at least 48 hours after enrollment and for whom the ICU team had decided to initiate continuous sedative and/or opioid infusion(s). Patients admitted to the ICU after cardiac arrest or traumatic brain injury were excluded, as were patients receiving neuromuscular blocking agents, those enrolled in another trial, those previously enrolled in the current trial, or those for whom there was a lack of commitment to maximal treatment. Legally authorized surrogates provided written informed consent.

**METHODS**

We conducted this multicenter randomized controlled trial in 16 centers from January 2008 to July 2011, after approval from local institutional review boards. In preparation, we completed a 65-patient, 3-center pilot randomized trial. We conducted this multicenter randomized controlled trial in 16 centers from January 2008 to July 2011, after approval from local institutional review boards. In preparation, we completed a 65-patient, 3-center pilot randomized trial.
Patients were weaned from mechanical ventilation at the discretion of the ICU team. To standardize the assessment of a patient’s extubation readiness, respiratory therapists evaluated patients daily at their current ventilator settings for the following criteria: awake, adequate cough with suctioning, PaO₂ greater than 60 mm Hg, oxygen saturation greater than or equal to 90%, fraction of inspired oxygen less than or equal to 0.4, positive end-expiratory pressure less than or equal to 10 cm H₂O, respiratory rate less than or equal to 15 L/minute, no inotrope or vasopressor infusions, mean arterial pressure greater than 60 mm Hg, and no evidence of acute myocardial ischemia (ie, chest pain, consistent electrocardiogram findings, elevated biomarker levels, or new arrhythmia). If all criteria were met, a 1-hour trial of unassisted breathing was initiated, during which ventilatory support was withdrawn and the patient breathed spontaneously at the previous fraction of inspired oxygen through a t-tube circuit, a tracheostomy mask, or the ventilator circuit with continuous positive airway pressure of 5 cm H₂O. The breathing trial could be terminated if any of the following signs of failure persisted for more than 5 minutes: respiratory rate greater than 35/min, oxygen saturation less than 90%, heart rate greater than 140/min or a change in heart rate of 20% in either direction, systolic blood pressure less than 90 or greater than 180 mm Hg, or increased anxiety and diaphoresis. A breathing trial was successful if the patient could breathe without mechanical assistance for 1 hour. When patients passed a trial of unassisted breathing, respiratory therapists notified a physician with a view to extubation. Research staff recorded reasons for delayed extubation, and daily screening continued until extubation. If the patient did not pass the unassisted breathing trial, the previous ventilator settings were resumed and the screening and breathing trials were repeated daily until extubation. If reintubation occurred within 48 hours, study sedation procedures resumed.

Bedside nurses also assessed daily for delirium with the Intensive Care Delirium Screening Checklist. Patients in both groups were managed “off protocol” during periods of neuromuscular blockade, high-frequency oscillation, or palliative care.

**Outcomes**

The primary study outcome was time to successful extubation, defined as time from randomization to extubation (or tracheostomy mask) for 48 hours. Secondary outcomes included unintentional device removal (eg, endotracheal tubes), physical restraint use, delirium, neuroimaging in the ICU, tracheostomy, barotrauma, total doses of sedatives and analgesics during mechanical ventilation, organ dysfunction, ICU and hospital lengths of stay, and death. Twice daily, nurses and respiratory therapists recorded their additional clinical workload attributed to study procedures, using a 10-point visual analog scale (VAS), with 1 corresponding to “very easy” and 10 to “difficult.” For patients assigned to daily interruption, we measured the proportion of days during which sedation was interrupted.

**Statistical Analysis**

The sample size estimate assumed a median time to successful extubation of 7 days among controls and a 2-day reduction with the addition of daily interruption (hazard ratio 1.4). We determined that 205 patients per group would provide a power of 90%, with an α level of 5%.

Our primary analysis was based on an intention-to-treat principle whereby all patients were analyzed according to their original group allocation, regardless of whether they received the allocated treatment. We used the Kaplan-Meier method to estimate and plot the distributions of time to successful extubation and an unadjusted Cox proportional hazards model to estimate a hazard ratio. For the time-to-extubation analysis, the event occurred when a patient was extubated within 28 days from randomization and remained extubated for more than 48 hours. Patients who died before extubation or who were transferred to another institution before 28 days were censored at death or transfer. Patients undergoing with-
DAILY SEDATION INTERRUPTION IN MECHANICALLY VENTILATED CRITICALLY ILL PATIENTS

drawal of life support were censored when that decision was made.
We also conducted a per-protocol analysis of patients who had interrup-
tions on more than 75% of eligible study days and 1 prespecified subgroup analy-
sis, according to classification of a patient’s ICU admission as medical vs sur-
gical/trauma. We hypothesized that medical patients would benefit more
than surgical patients from daily interruption, given their anticipated longer
durations of mechanical ventilation and sedative infusions.
Descriptive data are presented as percentages, means, with standard
deviations for normally distributed variables, and medians with inter-
quartile ranges for nonnormally distributed variables. Sedative and opioid
doses are presented as midazolam and fentanyl equivalents, respectively.20
We converted Richmond Agitation Sedation Scale values to Sedation-
Agitation Scale scores for analyses (eTable 3).
To examine between-group differences in categorical variables, we used
χ² or Fisher exact tests, as appropriate. For dichotomous outcomes, we pre-
sent relative risks or hazard ratios and their 95% CIs. If all assumptions were
met for parametric analyses of the continuous variables, we used a 2-sample
t test; otherwise, we used a 2-sample Wil-
coxon rank sum test. Mean Sedation-
Agitation Scale and VAS scores per pa-
tient and mean differences with 95% CIs were calculated. All statistical tests were
2-sided and considered statistically sig-
nificant at α<.05. SAS version 9.2 and
S-Plus version 7.0 were used for statis-
tical analysis.
An independent data and safety
monitoring committee reviewed trial
progress and adverse events after ran-
domization of 67, 117, and 292 pa-
tients. They also reviewed blinded data
for 1 planned interim analysis after en-
rollment of 211 patients.

RESULTS
Participants
Patients were enrolled in 14 Canadian
and 2 US centers. Of 2091 eligible pa-
tients, 1661 were not enrolled, primar-
ily because of lack of an authorized de-
cision maker (24.3%), consent refusal
(22.3%), or physician refusal (10.8%) (FIGURE 1). Among 430 randomized
patients, 7 withdrew consent in the first
3 days of the study and were excluded
from the analysis.

Table 1. Baseline Characteristics

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Protocolized Sedation and Daily Interruption (n = 214)</th>
<th>Protocolized Sedation (n = 209)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, median (IQR), y</td>
<td>57 (46-70)</td>
<td>60 (49-70)</td>
</tr>
<tr>
<td>Women</td>
<td>93 (43.5)</td>
<td>92 (44.0)</td>
</tr>
<tr>
<td>Type of admissionb</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical</td>
<td>175 (81.8)</td>
<td>179 (86.1)</td>
</tr>
<tr>
<td>Surgical</td>
<td>30 (14.5)</td>
<td>22 (11.0)</td>
</tr>
<tr>
<td>Trauma</td>
<td>8 (3.7)</td>
<td>6 (2.9)</td>
</tr>
<tr>
<td>BMI, median (IQR)</td>
<td>28.2 (23.8-34.2)</td>
<td>28.6 (25.0-33.2)</td>
</tr>
<tr>
<td>APACHE II score, median (IQR)b</td>
<td>24.0 (18-28)</td>
<td>23.0 (19-29)</td>
</tr>
<tr>
<td>SOFA at day 1, median (IQR)c</td>
<td>7 (5-10)</td>
<td>6 (4-9)</td>
</tr>
<tr>
<td>Mechanical ventilation, median (IQR), d</td>
<td>2 (1-4)</td>
<td>2 (1-4)</td>
</tr>
<tr>
<td>Opioid infusions No. (%)</td>
<td>184 (87)</td>
<td>186 (89)</td>
</tr>
<tr>
<td>Days of infusion, median (IQR)</td>
<td>1 (1-3)</td>
<td>1 (1-3)</td>
</tr>
<tr>
<td>Benzodiazepine infusions No. (%)</td>
<td>169 (81)</td>
<td>163 (80)</td>
</tr>
<tr>
<td>ICU admission diagnosisd</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bacterial/viral pneumonia</td>
<td>39 (18.2)</td>
<td>47 (22.5)</td>
</tr>
<tr>
<td>Nonurinary sepsis</td>
<td>40 (18.7)</td>
<td>36 (17.2)</td>
</tr>
<tr>
<td>Other respiratory disease</td>
<td>22 (10.3)</td>
<td>21 (10.0)</td>
</tr>
<tr>
<td>Aspiration pneumonia</td>
<td>11 (5.1)</td>
<td>4 (1.9)</td>
</tr>
<tr>
<td>COPD</td>
<td>4 (1.9)</td>
<td>10 (4.8)</td>
</tr>
<tr>
<td>Postoperative respiratory disease</td>
<td>7 (3.3)</td>
<td>7 (3.3)</td>
</tr>
<tr>
<td>Urinary sepsis</td>
<td>3 (1.4)</td>
<td>9 (4.3)</td>
</tr>
<tr>
<td>Gastrointestinal perforation/rupture</td>
<td>6 (2.8)</td>
<td>5 (2.4)</td>
</tr>
<tr>
<td>Hepatic failure</td>
<td>6 (2.8)</td>
<td>4 (1.9)</td>
</tr>
<tr>
<td>Noncardiogenic pulmonary edema</td>
<td>5 (2.3)</td>
<td>4 (1.9)</td>
</tr>
<tr>
<td>Other</td>
<td>71 (33.2)</td>
<td>62 (29.7)</td>
</tr>
<tr>
<td>Pre-ICU conditions⁶</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alcohol use</td>
<td>49 (23.0)</td>
<td>44 (21.2)</td>
</tr>
<tr>
<td>Tobacco use</td>
<td>48 (22.5)</td>
<td>40 (19.3)</td>
</tr>
<tr>
<td>Any psychiatric condition</td>
<td>42 (19.6)</td>
<td>29 (14.4)</td>
</tr>
<tr>
<td>Any neurologic condition</td>
<td>33 (15.4)</td>
<td>36 (17.2)</td>
</tr>
<tr>
<td>Respiratory disease</td>
<td>17 (8.0)</td>
<td>26 (12.4)</td>
</tr>
<tr>
<td>Renal dysfunction</td>
<td>20 (9.4)</td>
<td>16 (7.7)</td>
</tr>
<tr>
<td>Habitual drug use</td>
<td>14 (6.5)</td>
<td>10 (4.8)</td>
</tr>
<tr>
<td>Liver disease</td>
<td>12 (5.6)</td>
<td>11 (5.3)</td>
</tr>
</tbody>
</table>

Abbreviations: APACHE II, Acute Physiology and Chronic Health Evaluation; BMI, body mass index (calculated as weight
in kilograms divided by height in meters squared); COPD, chronic obstructive pulmonary disease; ICU, intensive care
unit; IQR, interquartile range; SOFA, Sequential Organ Failure Assessment.
*Surgeon refers to admission from an operating room or postoperative recovery area.
²APACHE II score may range from 0 to 71, with higher scores indicating more severe disease.
³SOFA score may range from 0 to 24 points, with higher scores indicating more severe disease.
⁴Diagnoses in this category are mutually exclusive. The 10 most frequent diagnoses are listed, and the remainder are
categorized as "other."
⁵Pre-ICU conditions are listed in descending frequency: neurologic condition defined as stroke, seizure disorder, de-
mentia, neuromuscular disease, Parkinson disease, or other neurologic condition; psychiatric condition includes de-
pression, bipolar disorder, schizophrenia, anxiety disorder, or other psychiatric condition; respiratory disease de-
fined as home oxygen, carbon dioxide retention or baseline, or home ventilation; renal dysfunction defined as chronic
renal failure with creatinine level greater than 180 μmol/L, or chronic dialysis; liver disease defined as Child Pugh Grade
C or known esophageal varices; and habitual drug use other than tobacco or alcohol.

©2012 American Medical Association. All rights reserved.
Patient characteristics were similar in the 2 groups (Table 1). Eighty-four percent received medical diagnoses. At enrollment, 359 (84.9%) patients were receiving midazolam infusions; 334 (79.0%), fentanyl; 71 (16.5%), morphine; and 41 (9.5%), propofol. Propofol infusions were discontinued at enrollment according to the study protocol.

Outcomes
The median time to successful extubation was 7 days in both groups (hazard ratio, 1.08; 95% CI, 0.86-1.33; P = .52) (Figure 2). Adjustment for age, body mass index, Acute Physiology and Chronic Health Evaluation II score, and admission type gave consistent results (adjusted hazard ratio, 1.04; 95% CI, 0.83-1.31). Similarly, in a per-protocol analysis of patients who had interruptions on more than 75% of eligible study days, there was no difference in time to successful extubation between groups. There were no between-group differences in ICU or hospital lengths of stay, hospital mortality, rates of unintentional device removal, delirium, ICU neuroimaging, barotrauma, tracheostomy, or organ dysfunction (Table 2).

Table 3 summarizes data related to sedative and opioid administration. Patients who ever had a score of 4 or more on the Intensive Care Screening Delirium Checklist.©2012 American Medical Association. All rights reserved.

Figure 2. Kaplan-Meier Curves for Time to Successful Extubation

<table>
<thead>
<tr>
<th>Measure of Effect (95% CI)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Days to successful extubation, median (IQR)(^a)</td>
<td>HR, 1.08 (0.86 to 1.35)</td>
</tr>
<tr>
<td>Days in ICU, median (IQR)(^a)</td>
<td>Mean difference, −3.17 (−6.89 to 0.55)</td>
</tr>
<tr>
<td>Days in hospital, median (IQR)(^a)</td>
<td>Mean difference, −8.2 (−17.64 to 1.19)</td>
</tr>
<tr>
<td>ICU mortality, No. (%)</td>
<td>RR, 0.94 (0.67 to 1.32)</td>
</tr>
<tr>
<td>Hospital mortality, No. (%)</td>
<td>RR, 0.96 (0.73 to 1.21)</td>
</tr>
<tr>
<td>ICU-acquired organ failure and supportive therapies, No. (%)</td>
<td>RR, 1.12 (0.88 to 1.42)</td>
</tr>
<tr>
<td>ARDS</td>
<td>RR, 0.91 (0.78 to 1.07)</td>
</tr>
<tr>
<td>Vasopressors/inotropes</td>
<td>RR, 1.33 (0.91 to 1.94)</td>
</tr>
<tr>
<td>Renal replacement</td>
<td>RR, 0.94 (0.53 to 1.69)</td>
</tr>
<tr>
<td>Neuromuscular blockade</td>
<td>RR, 0.61 (0.35 to 1.07)</td>
</tr>
<tr>
<td>Unintentional device removal, No. (%)</td>
<td>RR, 0.82 (0.36 to 1.84)</td>
</tr>
<tr>
<td>Gastric tube</td>
<td>RR, 0.45 (0.17 to 1.17)</td>
</tr>
<tr>
<td>Endotracheal tube</td>
<td>RR, 1.68 (0.79 to 3.57)</td>
</tr>
<tr>
<td>Urinary catheter</td>
<td>RR, 0.61 (0.35 to 1.07)</td>
</tr>
<tr>
<td>Central venous or arterial catheter</td>
<td>RR, 0.85 (0.54 to 1.35)</td>
</tr>
<tr>
<td>Neuroimaging in ICU, No. (%)</td>
<td>RR, 1.25 (0.47 to 3.29)</td>
</tr>
<tr>
<td>Computed tomography</td>
<td>RR, 0.85 (0.54 to 1.35)</td>
</tr>
<tr>
<td>Magnetic resonance imaging</td>
<td>RR, 0.96 (0.87 to 1.07)</td>
</tr>
<tr>
<td>Physical restraint</td>
<td>RR, 0.96 (0.87 to 1.07)</td>
</tr>
<tr>
<td>Patients, No. (%)</td>
<td>RR, 0.96 (0.87 to 1.07)</td>
</tr>
<tr>
<td>Study days, mean (SD)</td>
<td>RR, 0.96 (0.87 to 1.07)</td>
</tr>
<tr>
<td>Delirium, No. (%)</td>
<td>RR, 0.73 (0.35 to 1.50)</td>
</tr>
<tr>
<td>Reintubation within 48 h, No. (%)</td>
<td>RR, 0.88 (0.63 to 1.23)</td>
</tr>
</tbody>
</table>

Abbreviations: ARDS, acute respiratory distress syndrome; HR, hazard ratio; ICU, intensive care unit; IQR, interquartile range; RR, relative risk.

©2012 American Medical Association. All rights reserved.

JAMA, November 21, 2012—Vol 308, No. 19

1989
tients in the interruption group received higher mean daily benzodiazepine doses (102 vs 82 mg/d midazolam equivalents; median, 8 [IQR, 0-86 vs median, 0 [IQR, 0-50]; P=.04) and a greater number of boluses per day (mean, 0.253 vs 0.177; P=.007). They also received higher daily opioid doses (1780 vs 1070 μg/d fentanyl equivalents; P<.001), both as infusion and boluses, and a greater number of opioid boluses per day (mean, 2.18 vs 1.79; P<.001).

**Protocol Adherence and Clinician Workload**

Adherence with daily interruption was 72.2% of all eligible study days for an average patient and 85.6% for all eligible patient-days. Fifty-three percent of patients missed at least 1 daily interruption, and 6 patients missed every scheduled interruption. The most common reasons for noninterruption were related to mechanical ventilation (38.5%), agitation or pain (16.3%), and first day of study (14.6%) (eTable 4). Infusions were reintiated at a dose exceeding 50% of the previous dose for 30 patients (14.1%) on a total of 47 days. Propofol infusions were administered to 28 patients, accounting for 3.0% of study days.

In the control group, 34 patients (16.4%) had infusions interrupted on 54 occasions, accounting for 2.3% of study days. Forty patients receiving propofol infusions accounted for 2.1% of study days.

Overall, mean Sedation-Agitation Scale scores per patient were similar in the 2 groups (3.28 [95% CI, 2.92 to 3.85] in the interruption group vs 3.23 in controls; 95% CI, 3.0 to 3.71, respectively; mean difference, 0.05; 95% CI, −0.10 to 0.19; P=.52). However, nurse workload was significantly higher in the interruption group (mean VAS score, 4.22 vs 3.80; 95% CI, 3.30 to 5.0 vs 2.98 to 4.40; mean difference, 0.41; 95% CI, 0.17 to 0.66; P=0.001). Respiratory therapist workload was similar in the 2 groups (mean VAS score, 3.69 in the interruption group vs 3.61 in controls; 95% CI, 2.62 to 4.67 vs 2.70 to 4.33, respectively; mean difference, 0.08; 95% CI, −0.20 to 0.36; P=.57). Adherence with the performance of spontaneous breathing trials and with extubation after a successful spontaneous breathing trial was similar in the 2 groups (eTable 5).

**Subgroup Analysis**

Contrary to our hypothesis, surgical and trauma patients randomized to daily interruption had significantly shorter time to successful extubation than those randomized to protocolized sedation alone (6 vs 13 days; hazard ratio 2.55; 95% CI, 1.40 to 4.55), whereas there was no difference among medical patients (9 vs 8 days; hazard ratio, 0.92; 95% CI, 0.72 to 1.18; P value for the interaction=.004). Baseline characteristics and outcomes of the surgical/trauma patients by randomization group are presented in the supplementary appendix (eTables 6 to 8).

### Table 3. Benzodiazepine and Opioid Administration

<table>
<thead>
<tr>
<th></th>
<th>Protocolized Sedation (n = 214)</th>
<th>Protocolized Sedation (n = 209)</th>
<th>Measure of Effect, Mean Difference (95% CI)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Midazolam equivalents</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total dose/patient, mg</td>
<td>1087 (4297)</td>
<td>1038 (4592)</td>
<td>48.4 (−804.4 to 901.2)</td>
<td>.91</td>
</tr>
<tr>
<td>Dose/patient/d, mg</td>
<td>102 (326)</td>
<td>82 (287)</td>
<td>19.23 (2.37 to 37.07)</td>
<td>.04</td>
</tr>
<tr>
<td>Dose/patient/d, infusion, mg</td>
<td>101 (325)</td>
<td>82 (287)</td>
<td>19.22 (1.92 to 36.53)</td>
<td>.03</td>
</tr>
<tr>
<td>Dose/patient/d, bolus, mg</td>
<td>0.99 (5.9)</td>
<td>0.49 (2.65)</td>
<td>0.50 (0.23 to 0.76)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Infusion, d</td>
<td>5.73 (6.42)</td>
<td>5.58 (5.91)</td>
<td>0.15 (−1.04 to 1.33)</td>
<td>.81</td>
</tr>
<tr>
<td>Boluses/d, No.</td>
<td>0.253 (1.145)</td>
<td>0.177 (0.808)</td>
<td>0.077 (0.020 to 0.134)</td>
<td>.007</td>
</tr>
<tr>
<td><strong>Fentanyl equivalents</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total dose/patient, μg</td>
<td>18997 (59928)</td>
<td>13 532 (23 219)</td>
<td>5464.6 (−3236.0 to 14 165.2)</td>
<td>.22</td>
</tr>
<tr>
<td>Dose/patient/d, μg</td>
<td>1780 (4135)</td>
<td>1070 (2066)</td>
<td>709.3 (522.0 to 897.7)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Dose/patient/d, infusion, μg</td>
<td>1664 (4070)</td>
<td>984 (2002)</td>
<td>679.7 (496.3 to 864.1)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Dose/patient/d, bolus, μg</td>
<td>116 (215)</td>
<td>86 (169)</td>
<td>30.13 (19.15 to 41.11)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Infusion, d</td>
<td>6.44 (6.86)</td>
<td>6.61 (6.20)</td>
<td>−0.17 (−1.42 to 1.09)</td>
<td>.79</td>
</tr>
<tr>
<td>Boluses/d, No.</td>
<td>2.18 (2.87)</td>
<td>1.79 (2.67)</td>
<td>0.395 (0.239 to 0.551)</td>
<td>&lt;.001</td>
</tr>
</tbody>
</table>

Conversion factors: For conversion of lorazepam to midazolam, 1 mg midazolam = 0.5 mg lorazepam. For conversion of opioids to fentanyl equivalents, 10 mg morphine = 2 mg hydrocodone = 0.1 mg fentanyl.

*Does are presented as mean (SD) in the first row and median (interquartile range) in the second row.
COMMENT

In this multicenter randomized trial, we found that among mechanically ventilated patients receiving continuous sedation, the combined use of protocolized sedation and daily sedative interruption did not improve on the clinical outcomes observed with protocolized sedation alone. Patients in the daily interruption group received more opioids and benzodiazepines, and self-assessed nursing workload was higher for patients in the daily interruption group than the control group; however, these findings are of uncertain clinical importance.

Our results contrast with those of 2 earlier trials supporting daily interruption of sedative infusions in mechanically ventilated adults.2,21 In the original single-center trial comparing daily interruption with usual care in 128 mechanically ventilated patients receiving sedative and opioid infusions, daily interruption was associated with shorter durations of mechanical ventilation and ICU stay and less neuroimaging.3 In that trial, research personnel were always present for sedation interruption and had decisional authority regarding resumption of infusions. In a 4-center study, investigators randomized 336 ICU patients receiving ventilation to daily interruption (with up to 4 hours of monitoring by research personnel) or to usual care without a sedation protocol or additional monitoring.21 Patients assigned to daily interruption had shorter durations of mechanical ventilation and ICU and hospital stay; however, unintentional extubation occurred more frequently.

Our study is distinct from these earlier trials. First, we compared a sedation strategy adding daily interruption to a control group strategy of protocolized sedation that targeted light sedation, which is likely superior to “usual care” of an earlier era. Second, in this pragmatic trial, sedation was not directed by research staff but was managed by bedside ICU staff with their usual patient assignments, according to well-tested study protocols. Third, the multicenter design reflects actual practice in ICUs with variable workloads and ICU staffing models. Finally, we enrolled surgical patients in addition to medical patients; in this small prespecified subgroup, daily interruption was unexpectedly associated with shorter time to extubation.

The potential benefit of nurse-directed sedation titration protocols to minimize sedation is recognized, although early trials testing this strategy have been conflicting. A nurse-directed sedation protocol compared with usual care among 322 medical patients resulted in shorter durations of mechanical ventilation and ICU and hospital stay.4 In contrast, no clinical benefits were found with a different nurse-directed protocol in another center, potentially related to advanced-practice nurses managing ventilators who were already routinely using sedation-minimization strategies.5 The effectiveness of any new intervention to minimize sedation likely depends on the local usual care.

In this trial, adherence with sedation interruption of 72% compares favorably with that achieved in previous trials (ranging from 25% to 70%) when research personnel were not managing patient sedation.16,22,23 Reluctance to interrupt sedation infusions is expressed clearly in clinician surveys and practice audits.11,12,24 Common clinical concerns include the potential for patient discomfort, respiratory distress, patient safety, and additional workload.13,14,25,26 These reservations may reflect our unexpected findings of greater opioid and benzodiazepine doses, more bolus doses, and greater nurse workload among patients in the daily interruption group.

Strengths of this trial, in addition to the multicenter pragmatic design, include a broad mix of patients and an assessment of perceived additional nursing workload associated with daily sedation interruption. This trial also has limitations. Blinding of caregivers was not feasible, we did not screen for drug withdrawal, and our results may not be applicable to patients receiving shorter-acting agents such as propofol or dexmedetomidine or to patients requiring deeper levels of sedation.

In conclusion, for critically ill patients receiving mechanical ventilation, when nurses implemented a sedation protocol that targeted light sedation, daily sedation interruption did not reduce the duration of mechanical ventilation, offered no additional benefits for patients, and may have increased both sedation and analgesic use and nurse workload.

Publisher Online: October 17, 2012. doi:10.1001 /jama.2012.13872

Author Affiliations: Division of Critical Care, Department of Medicine and Interdepartmental Division of Critical Care, St. Michael's Hospital and University of Toronto, Toronto, Ontario, Canada (Dr Mehta); Department of Pharmacy and Medicine, St. Michael's Hospital and University of Toronto, Toronto, Ontario, Canada (Dr Bury); Departments of Medicine, Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Canada (Dr Cook and Meade); Division of Critical Care, St. Joseph's Healthcare, Hamilton, Canada (Dr Cook); Clinical Epidemiology Program, Ottawa Hospital Research Institute and Faculty of Medicine, University of Ottawa, Ottawa, Canada (Dr Fergusson); Mount Sinai Hospital, Toronto (Ms Steinberg); Toronto General Hospital, Division of Respiratory, Interdepartmental Division of Critical Care, Faculty of Medicine, University of Toronto (Dr Granton); Interdepartmental Division of Critical Care and Department of Medicine, University Health Network and University of Toronto (Dr Herridge); Interdepartmental Division of Critical Care Medicine and Division of Respiratory, Department of Medicine, University Health Network and Mount Sinai Hospital, University of Toronto (Dr Ferguson); School of Pharmacy, Northeastern University, Boston, Massachusetts (Dr Devlin); Department of Medicine, Long Beach Memorial Medical Center, Long Beach, California (Dr Tanios); Division of Critical Care Medicine and Center for Health Evaluation and Outcome Sciences, St. Paul's Hospital and University of British Columbia, Vancouver (Dr Dodek); Departments of Medicine and Critical Care Medicine, Sunnybrook Hospital, Toronto (Dr Fowler); Interdepartmental Division of Critical Care Medicine (Dr Fowler and Burns) and Institute for Health Policy Management and Evaluation (Dr Burns), University of Toronto; Keenan Research Centre and the Li Ka Shing Knowledge Institute, St Michael's Hospital, Toronto (Dr Burns); Departments of Anesthesiology and Critical Care, University of Alberta Hospital, Edmonton, Canada (Dr Jacka); Section of Critical Care, Department of Medicine, Faculty of Medicine, University of Manitoba, Winnipeg, Canada (Dr Olafson); Center de Médecine, Soins Intensifs, Hôpital Maisonneuve Rosemont, Université de Montréal, Montréal, Canada (Dr Skrobik); Department of Critical Care, University of Ottawa, Ottawa, Canada (Dr Hébert); Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa (Ms Sabri); and the Department of Critical Care, Hamilton Health Sciences, Hamilton, Canada (Dr Meade).

Author Contributions: Dr Mehta had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Mehta, Bury, Cook, Fergusson, Steinberg, Dodek, Fowler, Burns, Skrobik, Hébert, Meade. Acquisition of data: Mehta, Bury, Cook, Steinberg, Granton, Herridge, Ferguson, Devlin, Tanios, Dodek, Fowler, Burns, Jacka, Olafson, Skrobik, Hébert, Sabri, Meade.

©2012 American Medical Association. All rights reserved.
Analysis and interpretation of data: Mehta, Burry, Cook, Fergusson, Granston, Ferguson, Devlin, Dodek, Fowler, Burns, Hébert, Sabri, Meade.

Drafting of the manuscript: Mehta, Burry, Cook, Fergusson, Fowler, Hébert.

Critical revision of the manuscript for important intellectual content: Fergusson, Steinberg, Granston, Hébert, Fergusson, Devlin, Tanios, Dodek, Fowler, Burns, Jacka, Olafson, Skrobik, Sabri, Meade.

Statistical analysis: Fergusson, Fowler, Hébert, Sabri.

Obtained funding: Mehta, Burry, Cook, Fergusson, Fowler, Meade.

Obtained funding: Mehta, Burry, Cook, Ferguson, Granston, Ferguson, Devlin, Dodek, Fowler, Burns, Jacka, Olafson, Skrobik, Sabri, Meade.

Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.

Funding/Support: Funding was provided by the Canadian Institutes of Health Research. Dr Cook is a Canadian Research Chair of the Canadian Institutes for Health Research. Dr Burns holds a Clinician Scientist Phase 2 Award of the Canadian Institutes for Health Research. Dr Fowler is a Clinician Scientist of the Heart and Stroke Foundation (Ontario).

Role of the Sponsor: The study sponsor had no role in the design of the study; the collection, analysis, or interpretation of the data; or the writing or approval of the manuscript.

Online-Only Material: The eAppendix, 2 figures, 8 eTables, and Author Audio Interview are available at http://www.jama.com.

Additional Contributions: We thank the Canadian Critical Care Trials Group for their collaboration and the ICU nurses for their dedication to patient care and their support of this study.

REFERENCES


